A Phase III, Single Arm, Multicentre Study to Evaluate the Efficacy and Safety of a Subcutaneous Four Months Sustained-release Formulation of Triptorelin, a Gonadotrophin Releasing Hormone Analogue in Patients With Prostate Cancer
Phase of Trial: Phase III
Latest Information Update: 18 Jan 2019
At a glance
- Drugs Triptorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Ipsen
- 31 Aug 2018 Biomarkers information updated
- 26 Jun 2012 Additional trial location (Portugal) added as reported by European Clinical Trials Database.
- 10 Jan 2007 New trial record.